Last reviewed · How we verify
AS 50% eye drops 8*1
AS 50% eye drops provide osmotic dehydration of corneal edema by drawing fluid from the cornea into the anterior chamber.
AS 50% eye drops provide osmotic dehydration of corneal edema by drawing fluid from the cornea into the anterior chamber. Used for Corneal edema (bullous keratopathy), Temporary improvement of vision in corneal edema.
At a glance
| Generic name | AS 50% eye drops 8*1 |
|---|---|
| Also known as | 50% autologous serum eye drops 8*1 |
| Sponsor | Seref istek |
| Drug class | Osmotic agent |
| Modality | Biologic |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Sodium chloride (hypertonic saline) at 50% concentration creates an osmotic gradient across the corneal epithelium, reducing corneal swelling and improving transparency. This mechanism is used to temporarily improve vision in patients with corneal edema and to facilitate corneal examination. The effect is reversible and symptomatic rather than curative.
Approved indications
- Corneal edema (bullous keratopathy)
- Temporary improvement of vision in corneal edema
Common side effects
- Ocular irritation or stinging
- Temporary blurred vision
- Hyperemia (redness)
Key clinical trials
- Efficacy and Safety of RTH258 Versus Aflibercept - Study 2 (PHASE3)
- Efficacy and Safety of RTH258 Versus Aflibercept - Study 1 (PHASE3)
- A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn (NA)
- Comparison of Efficacy Between 100% Platelet-rich Plasma and 100% Serum Eye Drops in Dry Eye Disease (PHASE3)
- The Comparison of 50% AS Versus PFAT+ 0.05 % COE in Severe Dry Eye Syndrome (PHASE4)
- S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AS 50% eye drops 8*1 CI brief — competitive landscape report
- AS 50% eye drops 8*1 updates RSS · CI watch RSS
- Seref istek portfolio CI